血栓形成倾向治疗市场按类型细分(莱顿因子 V、凝血酶原 20210、抗磷脂综合征等);药物(肝素、华法林等);以及最终用户(医院、家庭护理、专科中心等)——2030 年全球需求分析和机会展望。

  • 报告编号: 3706
  • 发布日期: Feb 07, 2023
  • 报告格式: PDF, PPT

 

Global Thrombophilia Treatment Market Highlights 2022 – 2030

The global thrombophilia therapeutics market is expected to grow at a significant CAGR during the forecast period, i.e. 2022 to 2030, thereby generating substantial revenue. The growth of the market can be attributed to the increasing burden of obesity along with the rising prevalence of cardiovascular and trauma cases across the world. According to the World Health Organization, cardiovascular diseases cause approximately 17.9 million deaths to date, which is approximately 32% of all deaths worldwide.

Apart from this, the increase in alcohol and tobacco consumption is expected to increase the risk of venous hypertension, leading to multiple thrombotic complications, which in turn is expected to drive the market growth over the next few years. Furthermore, increasing R&D expenditure in the field of blood disorders and government initiatives to create awareness about blood disorders are expected to provide lucrative opportunities to the market in the near future.

Thrombophilia Treatment Market

 

The market is segmented by end-user into hospitals, home care, specialty centers, and others, of which the hospital segment is expected to hold the largest share in the global thrombophilia treatment market. This can be attributed to the high willingness of patients to be treated by healthcare professionals operating in hospital facilities, as well as the increase in the number of hospitalizations. Furthermore, based on type, the Factor V Leiden segment is assessed to acquire the largest share during the forecast period, which can be attributed to the prevalence of this type of thrombophilia in the general population. Apart from this, the surge in the number of people with genetic mutations across the globe is also expected to drive the growth of this segment in the near future.

Key macroeconomic indicators that influence market growth

Healthcare spending

According to the World Health Organization, the global per capita healthcare expenditure was $1,064.741 in 2017. The global per capita healthcare expenditure increased from $864.313 in 2008 to $1,110.841 in 2018, with the United States ranking first. In 2018, the per capita healthcare expenditure was $10, or $623.85. As of 2018, the domestic general government healthcare expenditure in the United States was $5355.79, an increase from $3515.82 in 2008. These are some of the factors that have led to the growth of the market over the past few years. In addition, according to the Centers for Medicare and Medicaid Services (CMS), the estimated average annual percentage change in the National Health Expenditure (NHE) in the United States is 5.2% in 2020 compared to 2019 (4.5%). Moreover, the national health expenditure is expected to reach $6,192.5 billion in 2028, and the per capita expenditure is expected to reach $17,611. These noteworthy indicators are expected to create lucrative business opportunities in the coming years.

Regional Overview of Global Thrombophilia Treatment Market

Based on geographical analysis, the global thrombophilia treatment market is segmented into five major regions, namely North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The market in Asia Pacific is expected to witness significant growth during the forecast period owing to increasing investments in improving healthcare infrastructure and expanding patient base in the region. Furthermore, the North American market is expected to account for the largest share during the forecast period owing to the growing demand for progressive treatment options and early adoption of technology, especially in the U.S. In addition, the increase in the geriatric population and growing collaboration between domestic and foreign companies in awareness campaigns are also expected to drive market growth in the region in the coming years. According to data provided by the Rural Health Information Center, as of 2019, there were more than 46 million adults aged 65 years or above in the U.S. This number is expected to reach nearly 90 million by 2050.

Thrombophilia Treatment Market

 

The global thrombophilia therapeutics market is further categorized by region as follows:

  • North America (United States and Canada) Market Size, Year-on-Year Growth, Market Player Analysis and Opportunity Outlook
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market Size, Year-over-Year Growth and Market Player Analysis and Opportunity Outlook
  • Europe (UK, Germany, France, Italy, Spain, Hungary, Belgium, Netherlands and Luxembourg, Nordic (Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market Size, Year-on-year Analysis of Market Players and Opportunity Outlook
  • Asia Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific) Market size, year-on-year growth and market player analysis and opportunity outlook
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market Size, YoY Growth Market Player Analysis and Opportunity Outlook

market segmentation

Our in-depth analysis of the global thrombophilia therapeutics market includes the following segments:

By Type

  • V Factor Leiden
  • Prothrombin 20210
  • Antiphospholipid syndrome
  • others

By drug classification

  • heparin
  • Warfarin
  • others

By End User

  • Hospital
  • Home Care
  • Specialist Centre
  • others

Growth drivers

  • The global burden of obesity is growing
  • The prevalence of cardiovascular and trauma cases is increasing worldwide

challenge

  • Poor reimbursement policy provided by the government

Top featured companies dominating the market

  • Sanofi
    • Company Profile
    • Business strategy
    • main products
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Developments
    • Regional distribution
    • SWOT Analysis
  • Pfizer
  • Aspen Pharmaceuticals Holdings Ltd.
  • Boehringer Ingelheim GmbH
  • F. Hoffmann-La Roche GmbH
  • Mylan
  • Novartis
  • Opoklin SPA
  • SARIA SE & Co. KG


In-the-news

在新闻中

 

  • July 2021 - Sanofi highlights new research on first-in-class investigational therapies for hemophilia, immune thrombocytopenia and acquired thrombotic thrombocytopenic purpura .

  • September 2020 - Aspen Global Incorporated announced the divestiture of its wholly owned subsidiary incorporated in Mauritius, Mylan Ireland Limited, which will acquire all intellectual property rights related to Aspen’s thrombosis business in Europe1.

作者学分:  Radhika Pawar


  • 报告编号: 3706
  • 发布日期: Feb 07, 2023
  • 报告格式: PDF, PPT

常見問題 (FAQ)

推动市场增长的主要因素是全球肥胖负担的增加以及心血管和创伤病例患病率的增加。

预计市场在预测期内(即 2022 年至 2030 年)将实现显着的复合年增长率。

政府提供的不良报销政策预计将阻碍市场增长。

由于改善医疗基础设施的投资不断增加,以及该地区更大的患者群体,亚太地区将为市场增长提供更多商机。

市场上的主要参与者有赛诺菲公司、辉瑞公司、Aspen Pharmacare Holdings Limited、勃林格殷格翰有限公司等。

公司概况的选择基于产品细分市场产生的收入、公司的地理分布(决定创收能力)以及公司向市场推出的新产品。

市场按类型、药品、最终用户和地区进行细分。

预计医院领域将拥有最大的市场规模,并预计在预测期内以显着的复合年增长率增长,并显示出巨大的增长机会。
購買前詢問 索取免費樣品

  获取免费样品

免费样本副本包括市场概述、增长趋势、统计图表和表格、预测估计等等。

 索取免费样品副本

订购此报告之前如有疑问 ?

购买前询问